Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Avidity Biosciences, Inc. (RNA) Non-Current Assets (2019 - 2025)

Avidity Biosciences' Non-Current Assets history spans 7 years, with the latest figure at $159.6 million for Q4 2025.

  • For Q4 2025, Non-Current Assets rose 638.64% year-over-year to $159.6 million; the TTM value through Dec 2025 reached $470.2 million, up 517.65%, while the annual FY2025 figure was $159.6 million, 638.64% up from the prior year.
  • Non-Current Assets reached $159.6 million in Q4 2025 per RNA's latest filing, down from $168.2 million in the prior quarter.
  • In the past five years, Non-Current Assets ranged from a high of $168.2 million in Q3 2025 to a low of $2.8 million in Q1 2021.
  • Average Non-Current Assets over 5 years is $35.3 million, with a median of $16.9 million recorded in 2023.
  • Peak YoY movement for Non-Current Assets: decreased 3.53% in 2022, then skyrocketed 789.67% in 2025.
  • A 5-year view of Non-Current Assets shows it stood at $16.4 million in 2021, then decreased by 3.53% to $15.9 million in 2022, then grew by 8.77% to $17.2 million in 2023, then increased by 25.26% to $21.6 million in 2024, then soared by 638.64% to $159.6 million in 2025.
  • Per Business Quant, the three most recent readings for RNA's Non-Current Assets are $159.6 million (Q4 2025), $168.2 million (Q3 2025), and $118.4 million (Q2 2025).